JP2004508415A5 - - Google Patents

Download PDF

Info

Publication number
JP2004508415A5
JP2004508415A5 JP2002526415A JP2002526415A JP2004508415A5 JP 2004508415 A5 JP2004508415 A5 JP 2004508415A5 JP 2002526415 A JP2002526415 A JP 2002526415A JP 2002526415 A JP2002526415 A JP 2002526415A JP 2004508415 A5 JP2004508415 A5 JP 2004508415A5
Authority
JP
Japan
Prior art keywords
antibody
use according
medicament
route
medicament according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002526415A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004508415A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2001/028451 external-priority patent/WO2002022166A2/en
Publication of JP2004508415A publication Critical patent/JP2004508415A/ja
Publication of JP2004508415A5 publication Critical patent/JP2004508415A5/ja
Pending legal-status Critical Current

Links

Images

JP2002526415A 2000-09-14 2001-09-12 抗脈管形成因子としてのｔｗｅａｋレセプターアゴニスト Pending JP2004508415A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23235500P 2000-09-14 2000-09-14
PCT/US2001/028451 WO2002022166A2 (en) 2000-09-14 2001-09-12 Tweak receptor agonists as anti-angiogenic agents

Publications (2)

Publication Number Publication Date
JP2004508415A JP2004508415A (ja) 2004-03-18
JP2004508415A5 true JP2004508415A5 (https=) 2008-10-23

Family

ID=22872776

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002526415A Pending JP2004508415A (ja) 2000-09-14 2001-09-12 抗脈管形成因子としてのｔｗｅａｋレセプターアゴニスト

Country Status (9)

Country Link
EP (2) EP2260867A1 (https=)
JP (1) JP2004508415A (https=)
AR (1) AR030721A1 (https=)
AT (1) ATE515271T1 (https=)
AU (2) AU2001289019B2 (https=)
CA (1) CA2422095A1 (https=)
NZ (1) NZ525140A (https=)
TW (1) TWI275399B (https=)
WO (1) WO2002022166A2 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5550799B2 (ja) 1999-01-15 2014-07-16 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｔｗｅａｋのアンタゴニストおよびｔｗｅａｋレセプターのアンタゴニスト、ならびに免疫学的障害を処置するためのこれらの使用
US7495086B2 (en) * 1999-12-20 2009-02-24 Immunex Corporation TWEAK receptor
US6727225B2 (en) 1999-12-20 2004-04-27 Immunex Corporation TWEAK receptor
EP1239869B1 (en) 1999-12-20 2013-08-28 Immunex Corporation Tweak receptor
EA011607B1 (ru) 2002-04-09 2009-04-28 Байоджен Айдек Ма Инк. Способ лечения заболеваний, связанных с tweak
DE602004006871T2 (de) 2003-07-24 2008-02-07 Amgen Inc., Thousand Oaks Zusammensetzungen und verfahren, die multimere und oligomere lösliche fragmente des tweak-rezeptors betreffen
EP1566636A1 (en) * 2004-02-23 2005-08-24 AXARON Bioscience AG Use of Tweak modulators and inhibitors for the treatment of neurological conditions
AU2005227322A1 (en) 2004-03-23 2005-10-06 Biogen Idec Ma Inc. Receptor coupling agents and therapeutic uses thereof
EP2529619B1 (en) 2005-02-17 2015-09-23 Biogen MA Inc. Treating neurological disorders
WO2006096487A2 (en) * 2005-03-07 2006-09-14 Genentech, Inc. Methods and compositions for modulating tweak and fn14 activity
JP5339901B2 (ja) 2005-05-10 2013-11-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド 炎症傷害の処置および評価
DK1888113T3 (da) 2005-05-27 2014-09-01 Biogen Idec Inc Tweak-bindende antistoffer
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
WO2009020933A2 (en) 2007-08-03 2009-02-12 Facet Biotech Corporation Therapeutic use of anti-tweak receptor antibodies

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773319A (en) 1971-12-16 1973-11-20 Fabcor Ind Inc Corrugated sheet inverting machine
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
JP2001513626A (ja) * 1997-02-12 2001-09-04 アボツト・ラボラトリーズ 疾患の治療及び診断のために有用なｔｎｆファミリーのメンバー
WO1998055508A2 (en) 1997-06-03 1998-12-10 Sagami Chemical Research Center HUMAN PROTEINS HAVING TRANSMEMBRANE DOMAINS AND DNAs ENCODING THESE PROTEINS
JP5550799B2 (ja) * 1999-01-15 2014-07-16 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｔｗｅａｋのアンタゴニストおよびｔｗｅａｋレセプターのアンタゴニスト、ならびに免疫学的障害を処置するためのこれらの使用
CN1345334A (zh) * 1999-01-29 2002-04-17 伊姆克罗尼系统公司 对kdr特异的抗体及其应用
EP1239869B1 (en) * 1999-12-20 2013-08-28 Immunex Corporation Tweak receptor

Similar Documents

Publication Publication Date Title
JP2004508415A5 (https=)
KR101905208B1 (ko) Cd38을 특이적으로 인식하는 항체 및 보르테조밉을 함유하는 항종양 조합물
Jabbour et al. Monoclonal antibodies in acute lymphoblastic leukemia
KR101733252B1 (ko) Ｃｄ３８을 특이적으로 인식하는 항체 및 멜팔란을 함유하는 항종양 조합물
JP6130871B2 (ja) Ｃｄ３８を特異的に認識する抗体とビンクリスチンとを含有する抗腫瘍組合せ
RU2018119296A (ru) Конъюгаты антитела, содержащие агонисты толл-подобного рецептора
JP2019502676A5 (https=)
KR20110096552A (ko) Ｃｄ３８을 특이적으로 인식하는 항체 및 시클로포스파미드를 함유하는 항종양 조합물
JP2017510559A5 (https=)
KR20110096551A (ko) Ｃｄ３８을 특이적으로 인식하는 항체 및 시타라빈을 함유하는 항종양 조합물
WO2004050016A3 (en) Delivery of pharmaceutical agents via the human insulin receptor
WO2002045653A3 (en) Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody
JP2003517461A5 (https=)
JP2020510039A5 (https=)
AU2021271647A1 (en) Use of a multimeric anti-DR5 binding molecule in combination with a cancer therapy for treating cancer
CA2055615A1 (en) Monoclonal antibodies for inducing tolerance
Qi et al. A novel diphtheria toxin‐based bivalent human EGF fusion toxin for treatment of head and neck squamous cell carcinoma
JP2004523538A5 (https=)
Jabbour et al. Immunotherapy in adult acute lymphoblastic leukemia: the role of monoclonal antibodies
WO2019149219A1 (zh) 抗-cd3免疫毒素联合抗-pd-l1单域抗体治疗癌症的应用
Morgan Jr et al. Preclinical and clinical evaluation of a monoclonal antibody to a human melanoma-associated antigen
Parker et al. The Immunology of Sepsis
Carrasquillo Radioimmunotherapy of Non Hodgkins Lymphomas
Friedberg Novel Monoclonal Antibodies in the Treatment of Lymphoma
Abraham Neutralizing antibodies and receptor constructs